Open access
Sep 2026
Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.
Importance In the KEYNOTE-826 study, pembrolizumab (vs placebo) plus platinum-based chemotherapy (with or without bevacizumab) significantly improved progression-free survival and overall survival in participants with previously untreated persistent, recurrent, or metastatic cervical cancer at interim analysis 1 (media...
Kosei Hasegawa, N. Colombo, Krishnansu S. Tewari et al.
· JAMA Oncology · 0 citations